Cytokinetics EVP sells $72,360 in stock

Published 08/04/2025, 23:06
Cytokinetics EVP sells $72,360 in stock

Malik Fady Ibraham, the Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), recently executed a series of stock transactions according to the latest SEC filings. On April 8, 2025, Ibraham sold 2,000 shares of Cytokinetics common stock at an average price of $36.18 per share, totaling approximately $72,360.

In addition to the sale, Ibraham exercised options to acquire 2,000 shares at a price of $10.60 per share, amounting to $21,200. Following these transactions, Ibraham holds 140,255 shares directly. According to InvestingPro analysis, analyst price targets for CYTK range from $47 to $120, suggesting potential upside despite recent market pressure.

These transactions were conducted under a pre-arranged trading plan, as indicated in the filing. Investors often monitor such insider activities to gauge executive sentiment regarding the company's future performance. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro subscribers can access detailed financial health scores and 12 additional ProTips for CYTK.

In other recent news, Cytokinetics has been the focus of several analyst reports following developments in its cardiomyopathy treatment pipeline. H.C. Wainwright reaffirmed a Buy rating with a $120 price target, based on promising Phase 2 data for EDG-7500™, a treatment for hypertrophic cardiomyopathy (HCM). The trial showed significant improvements in cardiac stress indicators and quality of life for patients. Meanwhile, Cantor Fitzgerald maintained an Overweight rating, emphasizing the potential of Cytokinetics' heart failure treatment, Afi™, and its promising safety and efficacy profile. JMP Securities also reiterated a Market Outperform rating with a $78 price target, highlighting the encouraging results from the EDG-7500 trial despite safety concerns like atrial fibrillation. Raymond (NSE:RYMD) James maintained an Outperform rating with an $81 price target, noting the competitive landscape for HCM treatments and the potential benefits for Cytokinetics. Additionally, Morgan Stanley (NYSE:MS) kept an Overweight rating with a $67 price target, citing the differentiated safety profile of Cytokinetics' aficamten compared to competitors. These recent developments indicate a strong focus on Cytokinetics' ongoing trials and their potential impact on the treatment of cardiomyopathy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.